Abstract
The antitumor effects and toxicities of combination chemotherapies using cisplatin (CDDP) and its analogues were compared with those of single drug therapies. Congenitally athymic nude BALB/c (nu/nu) mice were used to estimate antitumor activities of these compounds against human testicular tumor (Ht‐14) xenografts and hetero‐BALB/c (nu/+) mice were used to evaluate the toxic effects of the drugs. Combination therapy with half dosages of CDDP and carboplatin (JM8) (CDDP: 2, JM8: 20 mg/kg/day for 5 days), or of CDDP and (glycolato‐O, O′)‐diammineplatinum (II) (254S) (CDDP: 2, 254S: 4 mg/kg/day for 5 days), resulted in significant tumor regression. The combination of CDDP and JM8 had the highest therapeutic efficacy while the CDDP and 254S combination had a lower antitumor potency. In addition, the toxicities of the combination therapies were lower than what was produced by the highest dosage of CDDP (4 mg/kg/day for 5 days). These results demonstrated that the antitumor activities of these combination chemotherapies were equal or superior to the activity of CDDP or an analogue alone, and that the toxicities produced by these combinations were more manageable than those produced by single drug therapies.
Keywords: Cisplatin, Cisplatinum analogue, Combination chemotherapy
Full Text
The Full Text of this article is available as a PDF (353.6 KB).
REFERENCES
- 1. ) Samson , M. K. , Rivkin , S. E. , Jones , S. E. , Costanzi , J. J. , LoBuglio , A. F. , Stephens , R. L. , Gehan , E. A. and Cummings , G. D.Dose‐response and dose‐survival advantage for high versus low‐dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study . Cancer , 53 , 1029 – 1035 ( 1984. ). [DOI] [PubMed] [Google Scholar]
- 2. ) Ozols , R. F. , Ihde , D. C. , Linehan , W. M. , Jacob , J. , Ostchega , Y. and Young , R. C.A randomized trial of standard chemotherapy vs a high‐dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ‐cell tumors . J. Clin. Oncol. , 6 , 1031 – 1040 ( 1988. ). [DOI] [PubMed] [Google Scholar]
- 3. ) Rozencweig , M. , Nicaise , C. , Beer , M. , Crespeigne , N. , Rijmenant , M. V. , Lenaz , L. and Kenis , Y.Phase I study of carboplatin given on a five‐day intravenous schedule . J. Clin. Oncol. , 10 , 621 – 626 ( 1983. ). [DOI] [PubMed] [Google Scholar]
- 4. ) van Echo , D. A. , Egorin , M. J. , Whitacre , M. Y. , Olman , E. A. and Aisner , J.Phase I clinical and pharmacologic trial of carboplatin daily for 5 days . Cancer Treat. Rep. , 68 , 1103 – 1114 ( 1984. ). [PubMed] [Google Scholar]
- 5. ) Wiltshaw , E. , Evans , B. and Harland , S.Phase III randomized trial cisplatin versus JM8 (carboplatin) in 112 ovarian cancer patients, stage III and IV . Proc. Am. Soc. Clin. Oncol. , 4 , 121 ( 1985. ). [Google Scholar]
- 6. ) Peckham , M. J. , Horwich , A. and Hendry , W. F.Advanced seminoma: treatment with cis‐platinum‐based combination chemotherapy or carboplatin (JM8) . Br. J. Cancer , 52 , 7 – 13 ( 1985. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. ) Trump , D. L. , Grem , J. L. , Tutsh , K. D. , Wilson , J. K. V. , Simon , K. J. , Alberti , D. , Storer , B. and Tormey , D. C.Platinum analogue combination chemotherapy: cisplatin and carboplatin — A phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion . J. Clin. Oncol. , 5 , 1281 – 1289 ( 1987. ). [DOI] [PubMed] [Google Scholar]
- 8. ) Sasaki , Y. , Tamura , T. , Eguchi , K. , Shinkai , T. , Fujiwara , Y. , Fukuda , M. , Ohe , Y. , Bungo , M. , Horichi , N. , Niimi , S. , Minato , K. , Nakagawa , K. and Saijo , N.Pharmacokinetics of (glycolato‐O, O')‐diammine platinum(II), a new platinum derivative, in comparison with cisplatin and carboplatin . Cancer Chemother. Pharmacol. , 23 , 243 – 246 ( 1989. ). [DOI] [PubMed] [Google Scholar]
- 9. ) Harstrick , A. , Casper , J. , Guba , R. , Wilke , H. , Poliwoda , H. and Schmoll , H. J.Comparison of the antitumor activity of cisplatin, carboplatin and iproplatin against established human testicular cancer cell lines in vivo and in vitro . Cancer , 63 , 1079 – 1083 ( 1989. ). [DOI] [PubMed] [Google Scholar]
- 10. ) Okada , K. and Yoshida , O.Study on heterotransplantation of malignant urogenital tumors in nude mice: results of transplantation and the characteristics of the explants . Acta Urol. Jpn. , 30 , 1749 – 1767 ( 1984. ). [PubMed] [Google Scholar]
- 11. ) Selby , P. J. , Heyderman , E. , Gibbs , J. and Peckham , M. J.A human testicular teratoma serially transplanted in immune‐deprived mice . Br. J. Cancer , 39 , 578 – 583 ( 1979. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. ) Tveit , K. M. , Fodstad , O. , Brogger , A. and Olsnes , S.Human embryonal carcinoma grown in athymic mice and in vitro . Cancer Res. , 40 , 949 – 953 ( 1980. ). [PubMed] [Google Scholar]
- 13. ) Edler von Eyben , F. , Trope , C. , Ljungberg , O. , Alm , P. , Wennerberg , J. and Gulberg , B.Histologic pattern and growth in two human testis cancers before and after transplantation to nude mice . Cancer , 50 , 2845 – 2853 ( 1982. ). [DOI] [PubMed] [Google Scholar]
- 14. ) Steel , G. G. , Countenay , V. D. and Peckham , M. J.The response to chemotherapy of a variety of human tumour xenografts . Br. J. Cancer , 47 , 1 – 13 ( 1983. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. ) Lapis , P. , Kopper , L. , Bodrogi , I. , Sugar , J. , Lapis , K. and Eckhardt , S.Characteristics and chemotherapeutic sensitivity of a human testicular cancer grown in artificially immunosuppressed mice . Oncology , 42 , 112 – 118 ( 1985. ). [DOI] [PubMed] [Google Scholar]
- 16. ) Schlappack , O. K. , Bush , C. , Delic , J. I. and Steel , G. G.Growth and chemotherapy of a human germ‐cell tumour line (GCT 27) . Eur. J. Cancer Clin. Oncol. , 24 , 777 – 781 ( 1988. ). [DOI] [PubMed] [Google Scholar]